Clusterin CSF levels in differential diagnosis of neurodegenerative disorders

Journal of the Neurological Sciences

Volumn 361, Issue , 2016, Pages 117-121

  Prikrylova Vranova, Hana ^a   Hényková, Eva ^a   Mareš, Jan ^a   Kaiserová, Michaela ^a   Menšíková, Kateřina ^a   Vaštík, Miroslav ^a   Hluštík, Petr ^a   Zapletalová, Jana ^a   Strnad, Miroslav ^a   Stejskal, David ^a   Kaňovský, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer disease; Clusterin; CSF; Neurodegeneration; Parkinson's disease

Indexed keywords

CLUSTERIN; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SHY DRAGER SYNDROME; CEREBROSPINAL FLUID; NEURODEGENERATIVE DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CLUSTERIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; TAU PROTEINS;

EID: 84958968277     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.12.023     Document Type: Article

References (31)

1. I.P. Trougakos The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches - a mini-review Gerontology 59 2013 514 523
2. A.M. Lidström, and et al. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease Exp. Neurol. 154 1998 511 521
3. P. Giannakopoulos, and et al. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study Acta Neuropathol. 95 1998 387 394
4. K. Sasaki, K. Doh-ura, Y. Wakisaka, and T. Iwaki Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies Acta Neuropathol. 104 2002 225 230
5. J. Chen, M. Wang, and I.V. Turko Mass spectrometry quantification of clusterin in the human brain Mol. Neurodegener. 7 2012 41
6. J. Gao, X. Huang, Y. Park, A. Hollenbeck, and H. Chen An exploratory study on CLU, CR1 and PICALM and Parkinson's disease PLoS ONE 6 2011 e24211
7. R. Killick, E.M. Ribe, R. Al-Shawi, B. Malik, C. Hooper, C. Fernandes, and et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway Mol. Psychiatry 19 2014 88 98
8. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J. Neurol. Neurosurg. Psychiatry 55 1992 181 184
9. M. Emre, D. Aarsland, R. Brown, D.J. Burn, C. Duyckaerts, Y. Mizuno, and et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease Mov. Disord. 22 2007 1689 1707
10. I.G. McKeith, D.W. Dickson, J. Lowe, M. Emre, J.T. O'Brien, H. Feldman, and et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 2005 1863 1872
11. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, and et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol. 6 2007 734 746
12. I. Litvan, Y. Agid, D. Calne, G. Campbell, B. Dubois, R.C. Duvoisin, and et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop Neurology 47 1996 1 9
13. S. Gilman, P.A. Low, and N. Quinn Consensus statement on the diagnosis of multiple system atrophy J. Neurol. Sci. 163 1999 94 98
14. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 5 1967 427 442
15. Y. Wang, X. Wang, H. Zhao, B. Liang, and Q. Du Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression J. Chemother. 24 2012 348 357
16. S. Pucci, P. Mazzarelli, F. Missiroli, F. Regine, and F. Ricci Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon Prog. Brain Res. 173 2008 555 573
17. A.M. Lidström, C. Hesse, L. Rosengren, P. Fredman, P. Davidsson, and K. Blennow Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke J. Alzheimers Dis. 3 2001 435 442
18. M. Thambisetty, A. Simmons, L. Velayudhan, A. Hye, J. Campbell, Y. Zhang, and et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease Arch. Gen. Psychiatry 67 7 2010 739 748
19. A. Hye, J. Riddoch-Contreras, A.L. Baird, N.J. Ashton, C. Bazenet, R. Leung, and et al. Plasma proteins predict conversion to dementia from prodromal disease Alzheimers Dement. 10 6 2014 799 807
20. S. Baig, M.J. Owen, J. Williams, P.G. Kehoe, and S. Love Clusterin mRNA and protein in Alzheimer's disease J. Alzheimers Dis. 28 2012 337 344
21. H. Gu, X. Wei, S. Chen, A. Kurz, U. Müller, T. Gasser, R.C. Dodel, M.R. Farlow, and Y. Du Association of clusterin gene polymorphisms with late-onset Alzheimer's disease Dement. Geriatr. Cogn. Disord. 32 2011 198 201
22. Z.C. Wu, J.T. Yu, Y. Li, and L. Tan Clusterin in Alzheimer's disease Adv. Clin. Chem. 56 2012 155 173
23. J.T. Yu, and L. Tan The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy Mol. Neurobiol. 45 2012 314 326
24. E. Silajdžić, L. Minthon, M. Björkqvist, and O. Hansson No diagnostic value of plasma clusterin in Alzheimer's disease PLoS ONE 7 2012 e50237
25. B. Schürmann, B. Wiese, H. Bickel, S. Weyerer, S.G. Riedel-Heller, M. Pentzek, and et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration J. Alzheimers Dis. 25 2011 421 424
26. Y.Y. Xing, J.T. Yu, W.Z. Cui, X.L. Zhong, Z.C. Wu, Q. Zhang, and L. Tan Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease J. Alzheimers Dis. 29 2012 515 519
27. C. Sihlbom, P. Davidsson, M. Sjögren, L.O. Wahlund, and C.L. Nilsson Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals Neurochem. Res. 33 2008 1332 1340
28. C.L. Maarouf, T.G. Beach, C.H. Adler, H.A. Shill, M.N. Sabbagh, T. Wu, and et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects Neurol. Res. 34 2012 669 676
29. H. Přikrylová Vranová, J. Mareš, M. Nevrlý, J. Zapletalová, P. Hluštík, and P. Kaňovský CSF markers of neurodegeneration in Parkinson's disease J. Neural Transm. 117 2010 1177 1181
30. K.D. van Dijk, W. Jongbloed, J.A. Heijst, C.E. Teunissen, H.J. Groenewegen, H.W. Berendse, W.D. van de Berg, and R. Veerhuis Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease Parkinsonism Relat. Disord. 19 2013 1079 1083
31. H. Přikrylová Vranová, E. Hényková, M. Kaiserová, K. Menšíková, M. Vaštík, J. Mareš, P. Hluštík, J. Zapletalová, M. Strnad, D. Stejskal, and P. Kaňovský Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia J. Neurol. Sci. 343 2014 (120-4)